FOXN4 Activators
FOXN4 Activators encompass a variety of chemical compounds that indirectly enhance the activity of FOXN4 through diverse signaling pathways and epigenetic mechanisms. Retinoic Acid, all trans plays a pivotal role by modulating gene expression related to FOXN4 through its interaction with retinoic acid receptors, which bind to DNA elements in the FOXN4 promoter region. Similarly, Wnt Agonist and GSK-3 Inhibitor XVI exert their influence via the Wnt/β-catenin signaling pathway. They stabilize β-catenin, promoting its nuclear translocation and subsequent interaction with transcription factors that regulate FOXN4 expression. The Hedgehog pathway activator, SAG 21k, also contributes by upregulating FOXN4 through the transcriptional modulation associated with this pathway. Additionally, Forskolin, by increasing intracellular cAMP levels and activating PKA, leads to the phosphorylation of transcription factors that may augment FOXN4 expression, underscoring the intricate interplay between second messenger systems and gene regulation.
The role of epigenetic modulators is equally significant in enhancing FOXN4 activity. Compounds like I-BET151 and 5-Azacytidine reshape the chromatin landscape, altering gene expression patterns in a manner that favors FOXN4 upregulation. Valproic Acid, through its HDAC inhibitory action, also contributes to this epigenetic regulation, potentially increasing FOXN4 expression by making its gene more accessible to transcriptional machinery. Moreover, inhibitors of the TGF-β signaling pathway, such as A 83-01 and SB 431542, provide a pathway-specific approach to enhance FOXN4 expression by relieving negative regulatory influences. PD 0325901 and BML-275 add further complexity to this regulatory network. By inhibiting the MEK and BMP pathways, respectively, they induce changes in gene expression that can lead to the upregulation of FOXN4, demonstrating the intricate web of signaling interactions that converge on the modulation of FOXN4 activity. These diverse mechanisms collectively underscore the multifaceted nature of FOXN4 regulation, highlighting the intricate balance of signaling pathways and epigenetic modifications in dictating its functional state.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid, all trans, a metabolite of Vitamin A, enhances FOXN4 activity by modulating gene expression. It interacts with retinoic acid receptors, which can bind to retinoic acid response elements in the promoter regions of target genes, including those regulating FOXN4, leading to its functional activation. | ||||||
Wnt Agonist | 853220-52-7 | sc-222416 sc-222416A | 5 mg 25 mg | $157.00 $609.00 | 23 | |
Wnt Agonist activates Wnt/β-catenin signaling, a pathway that can influence FOXN4 activity. By stabilizing β-catenin, it promotes its translocation to the nucleus where it can interact with transcription factors that modulate FOXN4 expression, thereby enhancing FOXN4's functional activity. | ||||||
SAG | 912545-86-9 | sc-212905 sc-212905A | 1 mg 5 mg | $166.00 $421.00 | 27 | |
SAG 21k, a Smoothened agonist, activates the Hedgehog signaling pathway. This activation can lead to the transcriptional upregulation of FOXN4, as Hedgehog signaling is known to interact with factors that can modulate FOXN4 expression, enhancing its functional activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin, an activator of adenylate cyclase, increases cAMP levels, which can enhance FOXN4 activity. Elevated cAMP activates PKA, leading to the phosphorylation of transcription factors that may upregulate FOXN4 expression, thus promoting its functional role. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
I-BET151, a BET bromodomain inhibitor, modulates chromatin structure and gene expression. By altering the transcriptional landscape, it can indirectly increase FOXN4 expression through epigenetic modifications, thereby enhancing FOXN4's functional activity. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, alters gene expression patterns. This epigenetic modulation can lead to the upregulation of FOXN4, as changes in DNA methylation patterns can affect genes regulating FOXN4 expression, thus enhancing its activity. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid, an HDAC inhibitor, influences gene expression through epigenetic modifications. By inhibiting HDAC, it can lead to a more relaxed chromatin state, potentially upregulating FOXN4 expression through changes in the accessibility of transcriptional machinery to FOXN4 gene. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A 83-01, a TGF-β receptor inhibitor, can indirectly enhance FOXN4 activity. By inhibiting TGF-β signaling, it may lead to alterations in gene expression patterns that upregulate FOXN4, as TGF-β signaling can negatively regulate pathways involved in FOXN4 activation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB 431542, a TGF-β receptor inhibitor, similarly to A-83-01, can indirectly enhance FOXN4 activity. It alters gene expression by inhibiting TGF-β signaling, potentially upregulating FOXN4 in processes where TGF-β negatively regulates FOXN4-involved pathways. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
BML-275, a BMP inhibitor, indirectly influences FOXN4 activity. By inhibiting BMP signaling, it can lead to changes in gene expression that upregulate FOXN4, since BMP signaling can regulate pathways that are involved in the modulation of FOXN4 expression. | ||||||